Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada

Mondher Mtibaa,1 Subhajit Gupta,2 Madhusubramanian Muthukumar,2 Jessica Marvel,3 Harneet Kaur,2 Ryotaro Ishikawa,3 Ron Olivenstein4 1Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharma AG, Basel, Switzerland; 4McGill...

Full description

Bibliographic Details
Main Authors: Mtibaa M, Gupta S, Muthukumar M, Marvel J, Kaur H, Ishikawa R, Olivenstein R
Format: Article
Language:English
Published: Dove Medical Press 2021-12-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
moderate to severe asthma
indacaterol acetate
glycopyrronium bromide
mometasone furoate
cost-effectiveness
health care payer perspective
canada
uncontrolled asthma
Online Access:https://www.dovepress.com/cost-effectiveness-of-once-daily-single-inhaler-indacaterol-acetate-gl-peer-reviewed-fulltext-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-of-once-daily-single-inhaler-indacaterol-acetate-gl-peer-reviewed-fulltext-article-CEOR

Similar Items